Dongfang Wang, Johannes Schneider-Thoma, Spyridon Siafis, Mengchang Qin, Hui Wu, Yikang Zhu, John M Davis, Josef Priller, Stefan Leucht
Long-acting injectable antipsychotics (LAIs) are primarily used for relapse prevention, but in some settings and situations, they may also be useful for acute treatment of schizophrenia. We conducted a systematic review and frequentist network meta-analysis of randomized-controlled trials (RCTs), focusing on adult patients in the acute phase of schizophrenia. Interventions were risperidone, paliperidone, aripiprazole, olanzapine, and placebo, administered either orally or as LAI. We synthesized data on overall symptoms, complemented by 17 other efficacy and tolerability outcomes...
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology